



There is a pressing need for new therapies for vascular access dysfunction, which contributes substantially to patient morbidity and mortality, requires corrective procedures, incurs catheter dependency, and imposes staggering health care costs” Nath and Allon (2017).

Extract:

“Vascular access dysfunction impedes the provision of effective hemodialysis. Dysfunction of arteriovenous fistulas (AVFs) largely reflects maturational failure, whereas dysfunction of arteriovenous grafts (AVGs) is mainly driven by recurrent stenosis and thrombosis at the venous anastomosis. There is a pressing need for new therapies for vascular access dysfunction, which contributes substantially to patient morbidity and mortality, requires corrective procedures, incurs catheter dependency, and imposes staggering health care costs.” Nath and Allon (2017).

Full Text

ReTweet if useful... Developing new therapies for vascular access dysfunction
<https://ctt.ec/Pfc9U+> @ivteam #ivteam

Click To Tweet

Reference:



Nath and Allon (2017) Challenges in Developing New Therapies for Vascular Access Dysfunction. Clinical journal of the American Society of Nephrology. September 11th. .

Thank you to our partners for supporting IVTEAM

